• Geno Germano, President U.S. and General Manager Pharmaceuticals, Wyeth
• Rod MacKenzie, Senior Vice President, Head of Worldwide Discovery Research, Pfizer Inc.
• Jean-Marc Huet, Senior Vice President & Chief Financial Officer, Bristol-Myers Squibb
• Corey Goodman, President, Biotherapeutics and Bioinnovation Center, Pfizer
• Paul Clancy, Executive Vice President, Finance and Chief Financial Officer , Biogen IDEC*
• Tony Rosenberg, Head of Global Business Development & Licensing, Novartis Pharma AG
• James J. Dolan, Senior Vice President, Licensing & Business Development, Purdue Pharma
• Adelene Q. Perkins, EVP & Chief Business Officer, Infinity Pharmaceuticals Inc.
• Dennis Purcell, Senior Managing Partner, Aisling Capital
• Francesco De Rubertis, Partner, Index Ventures
• Michael Ross, PhD, Managing Partner, SV Life Sciences
• Ryan Mueller, Managing Director, Monument Group
• David Lacey, MD, Senior Vice President, Head of Research, Amgen*
• Christoph Westphal, CEO, Sirtris Pharmaceuticals, a GSK Company, Head of the CEEDD (Center of Excellence for External Drug Discovery, Glaxosmithkline
• Deborah Dunsire, President & CEO, Millennium, a Takeda Pharmaceuticals Company
• Alexander J. Denner,Managing Director, Icahn Partners LP
• William Slattery, Partner, Deerfield Management Company
• Alan Eisenberg, EVP, Emerging Companies and Business Development, BIO
• Tyrone Edwards, President, The Thompson Consulting Group of Springhouse; Former SVP Sales & Operations, Merck & Co.
• Richard Smith, Partner, Life Science Practice, Edwards Angell Palmer & Dodge LLP

*invited

What's on the agenda?

Windhover’s must-attend event examines and explains the most important strategic alliances of the last year, and looks ahead to what the industry can expect in the upcoming year.

• Big Pharma Mergers: Why? And What Will They Mean to You?
• Standalones: Can biotechs be successfully run as standalones within Pharma?
• Panel with Heads of Discovery: What is the role of discovery in new Pharma structures?
• The Future of Primary Care
• The Impact of Obama’s Administration on Pharma
• Past Big Pharma Executive Perspective: What should Big Pharma do next?
• Interesting Deal Structures: Keeping our options open and shelters for the financial storm
• What's Next for Private Exits?  Implications and complications for growing private biotechs
• Option Deals, Opt-Ins and Options to Acquire
• Dealmaking Trends, Data and Analysis
  Roger Longman, Managing Partner, Windhover Information

Also included are the following top-level workshops: "Rebuilding an Industry - One opportunity at a time" Presented by NovaQuest. More Information. "Two points of View: the licensing candidate value proposition from the emerging company and big pharma perspective" Presented by The Mattson Jack Group. More Information. "Biotechs on the Brink: Only the Focused Can Survive" Presented by Easton Associates. More Information.

Click to download the brochure (PDF) Please make plans to join us in New York this April for Pharmaceutical Strategic Outlook and BIO-Windhover, FDC-Windhover's premier strategic and partnering conferences being held concurrently this year. Some plenary sessions and networking events are open to attendees of both conferences. Other program elements (such as partnering or panel sessions) are only open to registrants of one or the other conference. Take the opportunity to not only find the partners you need, but to learn the latest successful strategies from top dealmakers, all in one week! Receive a 30% discount when you register for both.